-
111.发明授权公开(公告)号：US10766965B2
公开(公告)日：2020-09-08
申请号：US15160476
申请日：2016-05-20
Applicant: Janssen Biotech, Inc. , Tufts Medical Center, Inc.
Inventor： Chakra Chaulagain , Raymond Comenzo , Parul Doshi , Xun Ma , Amy Sasser
IPC: C07K16/28 , A61K39/395 , A61K9/00 , A61K31/573 , A61K31/664 , A61K31/69 , A61K38/05 , A61K38/47 , A61K45/06 , A61K39/00
Abstract: The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.
-
公开(公告)号：US10765724B2
公开(公告)日：2020-09-08
申请号：US15471790
申请日：2017-03-28
Applicant: Janssen Biotech, Inc.
Inventor： Marc Chevrier , Kamyar Farahi , Newman Yeilding
IPC: A61K38/20 , A61K39/395 , C07K16/24 , A01K67/027 , A61K39/00 , C07K14/54 , A61K35/12
Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
-
公开(公告)号：US20200277393A1
公开(公告)日：2020-09-03
申请号：US16878209
申请日：2020-05-19
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
114.发明申请公开(公告)号：US20200231693A1
公开(公告)日：2020-07-23
申请号：US16840830
申请日：2020-04-06
Applicant: Janssen Biotech, Inc.
IPC: C07K16/28
Abstract: The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them.
-
公开(公告)号：US20200170884A1
公开(公告)日：2020-06-04
申请号：US16631804
申请日：2017-07-20
Applicant: Janssen Biotech, Inc.
Inventor： Paul Tashjian
Abstract: A drug mixing device is disclosed. The drug mixing device comprises a transfer member, comprising an aperture for dispensing a fluid, wherein the fluid is a first component of a drug to be mixed. The drug mixing device also comprises a container for containing a second component of the drug to be mixed, the container comprising a surface. The aperture is configured to determine the initial direction of the velocity of the fluid dispensed through the aperture and further configured to direct the dispensed fluid towards the surface. The aperture and the surface are arranged relative to each other to cooperate such that, in use, substantially all of the dispensed fluid initially encounters the surface at an oblique angle.
-
Patent Agency Ranking
116.发明授权公开(公告)号：US10669344B2
公开(公告)日：2020-06-02
申请号：US15662866
申请日：2017-07-28
Applicant: Janssen Biotech, Inc.
Inventor： Anthony Armstrong , Mark Chiu , Di Zhang
Abstract: The present invention relates to engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions.
-
公开(公告)号：US10669343B2
公开(公告)日：2020-06-02
申请号：US15228582
申请日：2016-08-04
Applicant: Janssen Biotech, Inc.
Inventor： Johan Fransson , Galina Obmolova , Anish Suri , Fang Teng , Alexey Teplyakov , Hong Zhou , Jocelyn Leu
IPC: A61K39/395 , C07K16/28 , A61K45/06
Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US20200163834A1
公开(公告)日：2020-05-28
申请号：US16631733
申请日：2017-07-20
Applicant: Janssen Biotech, Inc.
Inventor： Paul Tashjian
IPC: A61J1/20
Abstract: A drug mixing device is disclosed. The drug mixing device comprises a container for containing a fluid component of a drug to be mixed and a housing. The housing comprises an inlet aperture configured to be connected to a fluid driver for driving a driving fluid into the container and an outlet aperture configured to permit the fluid component of the drug to be mixed to leave the container. The apertures are arranged such that the driving fluid enters the container through the inlet aperture, and additionally arranged such that the fluid component exits the container through the outlet aperture, the driving fluid having a lower density than the fluid component. The inlet aperture and the outlet aperture are arranged such that, in use, the inlet aperture is located above the outlet aperture.
-
公开(公告)号：US20200148736A1
公开(公告)日：2020-05-14
申请号：US16746052
申请日：2020-01-17
Applicant: Janssen Biotech, Inc.
Inventor： Thomas Rutkoski , Alexey Teplyakov , Nicole Wunderler
IPC: C07K14/535 , A61K45/06 , A61K38/19
Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
-
120.发明申请公开(公告)号：US20200095315A1
公开(公告)日：2020-03-26
申请号：US16580509
申请日：2019-09-24
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johans , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
-
-
-
-
-
-
-
-
Search Results
1019
records
(took 0.028 seconds)
